All variables were expressed in mean ± SD.DM = Diabetes Mellitus.*a: control group vs. focal & diffuse (surgical group), b: focal group vs. diffuse group.Baseline of characteristics of patients.
To evaluate 96-week virologic, immunologic, resistance and metabolic outcomes of bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) in antiretroviral therapy (ART)-naïve people li